Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
These re-agent and diagnostic test kits come with 99.7% accuracy
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Demonstrate significant bleed reduction in hemophilia A and B
Subscribe To Our Newsletter & Stay Updated